The global immunotherapy drugs market is a rapidly growing therapeutic area owing to the increasing prevalence of cancer worldwide. Immunotherapy drugs work by stimulating or suppressing the immune system’s response against cancer cells and are increasingly becoming a mainstream treatment approach. Some of the key advantages of immunotherapy drugs include high specificity for cancer cells with low toxicity for normal cells. The immunotherapy drugs market is projected to exhibit significant growth due to the rising preference for novel targeted therapies, development of innovative drug candidates, and increasing research focus on combination regimens.
The Global immunotherapy drugs market is estimated to be valued at US$ 166.55 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the immunotherapy drugs market are Infineon Technologies AG, STMicroelectronics, Deutsche Telekom AG, Giesecke+Devrient Mobile Security GmbH, Thales Group, KORE Wireless, Arm Limited, Truphone Limited, Workz Group, Sierra Wireless, NXP Semiconductors, and AT&T. The increasing incidence of cancer worldwide is a major factor driving the demand for immunotherapy drugs in recent years. According to WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. Additionally, the availability of advanced diagnostic technologies and increased public awareness is also boosting the immunotherapy drugs market growth.
Key players are investing heavily in R&D to develop novel and innovative drug candidates with better efficacy and safety profiles. Several pharma giants are also focusing on combination therapies involving immunotherapy drugs to expand the treatment options.
The Immunotherapy Drugs Market size is witnessing significant expansion in emerging economies of Asia Pacific and Latin America, owing to improving healthcare infrastructure and increasing spending on cancer treatment.
Market key trends
One of the key trends witnessed in the immunotherapy drugs market is the increasing focus on combination regimens. Combining immunotherapy drugs with conventional treatment regimens such as chemotherapy is emerging as a promising treatment approach with synergistic effects. Ongoing research emphasizes exploring different combination strategies involving immunotherapy drugs and targeted therapies to achieve optimal clinical outcomes. This is expected to enhance the efficacy of cancer treatments and contribute to market revenue growth over the forecast period.
Porter’s Analysis
Threat of new entrants: New entrants face significant challenges as immunotherapy space requires heavy investments in R&D and high costs associated with clinical trials.
Bargaining power of buyers: Customers face lack of alternatives and therapies within immunotherapies domain, hence buyers have low bargaining power.
Bargaining power of suppliers: Suppliers incl. pharmacos require specialized skillsets, hence have moderate bargaining power.
Threat of new substitutes: Limited substitutes exist for immunotherapies as they offer novel mechanisms of action with minimal toxicity.
Competitive rivalry: The Immunotherapy Drugs Market Challenges and Opportunities are characterized by fierce competition among leading brands continually innovating and improving technologies.
Immunotherapy drugs market in terms of value is concentrated majorly in North America and Europe. North America alone holds around 50% value share owing to high adoption and availability of reimbursement of these novel drugs.
Asia Pacific region is expected to emerge as the fastest growing regional market for immunotherapy drugs over forecast period from 2024 to 2031. This is attributed to factors such increasing awareness, rising healthcare investments, growing cancer incidence and improving access to modern therapies in emerging Asian countries like China and India.
Unlock More Insights—Explore the Report in the Language You Prefer
French German Italian Russian Japanese Chinese Korean Portuguese
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. LinkedIn